This systematic review and network meta-analysis found that spinal cord stimulation therapies for treatment of chronic pain in back and/or lower extremities were associated with greater improvements ...

A key highlight of the quarter came right at the end when Nevro won FDA approval for HFX AdaptiveAI, an AI-powered, ...

Transcutaneous Spinal Cord Stimulation Enables Recovery of Walking in Children with Acute Flaccid Myelitis Go to source) ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

Researchers at Kennedy Krieger Institute's International Center for Spinal Cord Injury (ICSCI) have made a remarkable ...

HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud ...

Researchers at Kennedy Krieger Institute report that Transcutaneous Spinal Cord Stimulation (TSS) combined with movement ...

US-based device company Nevro has secured market authorisation from the European Union (EU) for its HFX iQ spinal cord ...

Researchers at Kennedy Krieger Institute's International Center for Spinal Cord Injury (ICSCI) have made a remarkable advancement in treating children with Acute Flaccid Myelitis (AFM), a rare but ...

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

Nevro's HFX iQ spinal cord stimulator earned the European Union's CE mark, the company said Nov. 12.